Vectus Biosystems Limited announce that its Phase I/Ib trial, entitled: "A phase I/Ib, first-time-in-human, single centre, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk", has received approval from the Human Research Ethics Committee of the Alfred Hospital, Melbourne. The trial has been registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov), and has been provided with the identifier NCT04925050. The trial may be tracked using this number on the ClinicalTrials.gov public website. The trial site (Nucleus Network, Alfred Campus) will commence the process of recruitment and screening of study subjects in July 2021 for this first-in-human trial. The first component will be what is termed a Single Ascending Dose (SAD) study. In this SAD study a cohort or group of eight subjects (six treated and two placebo) will receive a single nominated dose of VB0004 on one occasion. The dose level is then escalated and the process repeated. This continues until the maximal dose has been reached and this segment of the trial is completed.